KLTO
Klotho Neurosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.38
−7.10%Price chart
Mar 13Mar 18Mar 23Mar 26Mar 31Apr 6Apr 9Apr 14
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
Market Cap
$22.64M
MomentumView details →
1D Return
−7.10%
YTD Return
+19.69%
RSI (14)
47.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
Market Cap
$22.64M
RSI (14)
47.6
MomentumView details →
1D Return
−7.10%
YTD Return
+19.69%
SummaryUpdated Sep 1, 2025
Klotho Neurosciences, Inc. (NASDAQ:KLTO) is an early-stage biopharmaceutical company focused on developing gene therapies for neurodegenerative diseases, cancer, and cardiovascular disorders. Originally founded as Anew Medical, Inc., the company rebranded to Klotho Neurosciences in September 2024 to reflect its focus on therapies based on the klotho protein, which plays a crucial role in aging and longevity. Headquartered in Omaha, Nebraska, the company is currently in the preclinical development stage with no approved products or revenue generation.
Similar companies
Latest newsMore news →
Greenland Mines Ltd, through its subsidiary Greenland Rare Earths Corp., amended its merger agreement to acquire Neo North Star Resources, Inc., substituting NNSR Holdings Inc. as the sole stockholder of Neo and fixing the equity consideration at 1,040,676 common shares and 359,324 preferred shares, with total consideration of US$20 million in cash plus equity shares.4h agoGreenland Mines announced it will close its acquisition of Sarfartoq Rare Earths by September 1, 2026, after securing Government of Greenland approval and completing a public offering to fund the deal.8d agoGreenland Mines Ltd signed a Securities Purchase Agreement to sell 1,632,783 shares of common stock and pre-funded warrants for up to 2,367,517 shares at $5.00 per share, expecting net proceeds of approximately $18.5 million, with the offering expected to close on August 27, 2026.9d ago